Crizanlizumab reduces priapic events in men with sickle cell disease
Crizanlizumab was associated with a halved likelihood of priapic events in treated patients with sickle-cell priapism, according to results from a phase 2 trial. In new data from the SPARTAN trial presented at the 2022 American Society of Hematology (ASH) annual meeting in New Orleans last week, a team of American researchers observed that the …
Crizanlizumab reduces priapic events in men with sickle cell disease Read More »
